• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » LivaNova implants first patient in Osprey obstructive sleep apnea study

LivaNova implants first patient in Osprey obstructive sleep apnea study

February 25, 2022 By Sean Whooley

LivaNova aura6000
[Image from LivaNova]
LivaNova (NSDQ:LIVN) announced that it completed the first patient implant in a study of its LivaNova aura6000 system.

London-based LivaNova designed the aura6000 system to maintain muscle tone of the tongue and upper airway so that airway obstruction and resulting sleep apnea are significantly reduced or eliminated. The hypoglossal neurostimulator system includes a programmable, rechargeable and implantable pulse generator (IPG) implanted in a subcutaneous pocket near the patient’s clavicle during an outpatient procedure.

The IPG generates mild stimulation that is delivered via lead to the hypoglossal nerve, stimulating the patient’s tongue during sleep to keep the airway open as an alternative to the traditional CPAP machine, according to a news release. The company said the aura6000 system allows patients to sleep without being connected to masks, hoses or mouthpieces.

LivaNova is conducting the Osprey FDA investigational device exemption (IDE) study of aura6000 at approximately 20 sites in the U.S., with plans to enroll a maximum of 150 adult patients with moderate to severe obstructive sleep apnea (OSA) who do not achieve results from a traditional CPAP machine or have declined its use.

The first OSPREY patient was implanted by Dr. Mitchell Miller at BayCare’s Morton Plant Hospital in Clearwater, Florida.

“Approximately 1 billion people worldwide live with OSA, but most are undiagnosed and untreated, which can seriously impact their health, increasing the rates of death, stroke, hypertension, motor vehicle accidents, heart failure, diabetes, depression and daytime sleepiness,” LivaNova CEO Damien McDonald said in the release. “There is a great need to offer patients diagnosed with OSA new and less restrictive treatment options. The Osprey study will be the first RCT to confirm efficacy of hypoglossal nerve stimulation and now, with the first Osprey patient implanted, we are another step closer to successfully bringing the innovative aura6000 system to market.”

Filed Under: Clinical Trials, Food & Drug Administration (FDA), Implants, Neuromodulation/Neurostimulation, Respiratory Tagged With: FDA, LivaNova

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy